Trials / Completed
CompletedNCT04945031
The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 317 (actual)
- Sponsor
- Mahidol University · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | cannabis | This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart. |
Timeline
- Start date
- 2019-11-08
- Primary completion
- 2020-05-31
- Completion
- 2020-12-31
- First posted
- 2021-06-30
- Last updated
- 2021-06-30
Locations
1 site across 1 country: Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04945031. Inclusion in this directory is not an endorsement.